CClinicalTrials.gg
CompletedNCT03219125ADIMOSUpdated Nov 4, 2022

Bone Marrow Adiposity and Fragility Fractures in Postmenopausal Women

An observational study in Fractures, Bone, Bone Marrow Disease and Fat Disorder, sponsored by University Hospital, Lille. Completed at 1 site in France. Open to female participants aged 50 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-04.

Sponsored by University Hospital, Lille · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
203
Ages
50 Years to 90 Years
Sex
Female
01

Study summary

The purpose is to determine in a case-control study if an association exist between bone marrow adiposity and fragility fractures in post-menopausal women.

02

Conditions studied

  • Fractures, Bone
  • Bone Marrow Disease
  • Fat Disorder
  • Adiposity

Keywords

  • marrow adipose tissue
  • bone marrow adiposity
03

In context

Bone Marrow Diseases

200 studies on the registry are indexed under Bone Marrow Diseases; 34 are open to participants now.

This study's enrollment of 203 is above the median of 80 across 59 observational studies indexed under Bone Marrow Diseases.

Browse Bone Marrow Diseases studies →

Lead sponsor

University Hospital, Lille is the lead sponsor of 625 studies on the registry; 141 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 90 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Post-menopausal women

Inclusion criteria

  • post-menopausal women : 50-90 years old
  • Group 1 (cases) : occurence of incident major osteoporotic fracture less than 12 months
  • Group 2 (controls) : no history of fragility fracture

Exclusion criteria

Exclusion Criteria:

  • Implants that are contraindicated for the magnetic resonance (MR) examination.
  • Implants that might create a health risk or other problem during an MR exam include: 1) cardiac pacemaker or implantable defibrillator, 2) catheter that has metal components that may pose a risk of a burn injury, 3) a ferromagnetic metal clip placed to prevent bleeding from an intracranial aneurysm, 4) an implanted medication pump (such as that used to deliver insulin or a pain-relieving drug), and 5) a cochlear implant.
  • body mass index [BMI] >38 kg/m2, weight >140 kg
  • Disease or current use of medications known to affect bone density, including oral glucocorticoids, treatments for osteoporosis (bisphosphonates, raloxifene, calcitonin, or PTH), hormone therapy.
  • Chronic kidney disease with DFG \<30 ml/mn
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
203 participants (actual)
Patient registry
No

Groups and cohorts

  • Group 1 (cases)

    occurence of incident major osteoporotic fracture less than 12 weeks

    Device: Dixon Magnetic Resonance Imaging

  • Group 2 (controls)

    no history of fragility fracture

    Device: dual-energy X-ray absorptiometry (DXA)

Interventions

  • DeviceDixon Magnetic Resonance Imaging

    MRI of the lumbar spine (L1 to L4) and hip (non-dominant) for the measurement of Ad Med. (In%) by the DIXON sequence.

  • Devicedual-energy X-ray absorptiometry (DXA)

    Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.

06

What researchers measure

Primary outcomes

  1. Bone marrow fat content at lumbar spine

    Total bone marrow fat content (percentage) at lumbar spine (L1-L4) measured with magnetic resonance imaging

    Time frame: 24 months

Secondary outcomes

  1. Bone marrow fat content at total hip

    Total bone marrow fat content (percentage) at total hip measured with magnetic resonance imaging

    Time frame: 24 months

  2. Bone mineral density at lumbar spine

    Bone mineral density (g/cm2) at lumbar spine (L1-L4) measured by DXA

    Time frame: 24 months

  3. Bone mineral density at total hip

    Bone mineral density (g/cm2) at total hip measured by DXA

    Time frame: 24 months

07

Study locations

1 site
  • Hôpital Roger Salengro, CHU
    Lille, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 4, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03219125
Lead sponsor
University Hospital, Lille
Responsible party
Sponsor
First posted
Jul 17, 2017
Start date
Oct 16, 2018
Primary completion
Jun 25, 2021
Completion
Jun 25, 2021
Last update
Nov 4, 2022

Study contacts

Julien Paccou, MD, PhD
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion